Full Press Release Details
SA Combined General Shareholders' Meeting of May 18, 2015
PARIS--(BUSINESS WIRE)--May 19, 2015--Regulatory News:
The Combined General Shareholders' Meeting of Cellectis S.A.
(Paris:ALCLS) (Alternext: ALCLS - Nasdaq Global Market: CLLS) was held
on Monday, May 18, 2015 in Paris, at the Group's headquarters.
At the end of the meeting, during which more than 75% of votes were
exercised, all of the ten resolutions submitted for the shareholders'
In particular, Cellectis' shareholders voted on:
the approval of the parent company and consolidated financial
statements for the fiscal year ended December 31, 2014;
term of office renewal of directors Mr Andr Choulika, Mr David
Sourdive and Mr Alain Godard;
the approval of regulated agreements;
the authorization of a share repurchase plan and the authorization
given to the Board of Directors to retire the shares acquired through
the nomination of a new Director, Mr Jean-Marie Messier.
Jean-Marie Messier, 58 years old, is co-founder and head of Messier
Maris & Associ s, an investment bank headquartered in Paris and
New-York. Messier Maris & Associ s is recognized as a leading
independent corporate finance advisor in mergers and acquisitions,
financial restructuring and equity / debt advisory.
The full results of the vote can be examined on the company's website (www.cellectis.com).
Cellectis is a gene-editing company focused on developing
immunotherapies based on gene edited engineered CAR-T cells (UCART). The
company's mission is to develop a new generation of cancer therapies
based on engineered T-cells. Cellectis capitalizes on its 15 years of
expertise in genome engineering - based on its flagship TALEN products
and meganucleases and pioneering electroporation PulseAgile technology -
to create a new generation of immunotherapies. CAR technologies are
designed to target surface antigens expressed on cells. Using its
life-science-focused, pioneering genome-engineering technologies,
Cellectis' goal is to create innovative products in multiple fields and
with various target markets. Cellectis S.A. is listed on the Nasdaq
Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker:
ALCLS). To find out more about us, visit our website: www.cellectis.com
Jennifer Moore, Director of
email: media@cellectis.com
email: bmiles@bmccommunications.com
Simon Harnest, VP Finance and Investor Relations
email: simon.harnest@cellectis.com